featured news

Wednesday, September 27, 2023

Launch of RABS

read more

feature 1

featured news

feature 2

featured news

feature 3

featured news

Thursday, June 8, 2023

Upcoming events

read more

feature 4

feature 5

featured news

Monday, March 6, 2023

DCAT Week 2023

read more

feature 6

featured news

feature 7

featured news

Thursday, February 2, 2023

Retrofit L2

read more

feature 8

featured news

feature 9

featured news

feature 10

featured news

Monday, September 19, 2022

CPHI 2022 Frankfurt

read more

feature 11

featured news

feature 12

featured news

Thursday, May 12, 2022

Line 3 Mock-up

read more

feature 13

featured news

feature 14

featured news

feature 15

featured news

Tuesday, September 8, 2020

central workplaces

read more

feature 17

our technological excellence as a CDMO

We are oncomed – a Contract Development and Manufacturing Organization (CDMO) specialized in aseptic processing of oncology injectables in clinical and commercial scales. We deliver drugs with high potent and cytotoxic characteristics to fight cancer, worldwide.

organic solvents handling

high-potent APIs

single-use systems

sensitive API handling

5 reasons why choose oncomed

5 reasons why choose oncomed

employee skills & mindset

We believe that thanks to our knowledge, flexible approach and endeavour to look for the solution, we may fully support a clients in their needs.

variety of niche technologies

We believe that thanks to our brave approach and state-of-the-art technology, our clients can dare to act with courage too and ask for advanced highly active drug solutions. We (and our technology) will support them.

supply risk mitigation

We understand the cost and time pressures faced by pharmaceutical companies, therefore we offer flexible, affordable, and rapid outsourcing services designed to meet specific needs of our customers.

access to free manufacturing capacity

We offer two fully operational lines. We also keep investing into manufacturing capacity and state-of-the-art technologies. Line 3 that will offer highly advanced solutions is in construction.

no additional major investments

We offer various vial formats, variable equipment sizes and qualified processes. We also take pride in our transparent service offerings that lower any additional investments to a mere minimum.

employee skills & mindset

We believe that thanks to our knowledge, flexible approach and endeavour to look for the solution, we may fully support a clients in their needs.

variety of niche technologies

We believe that thanks to our brave approach and state-of-the-art technology, our clients can dare to act with courage too and ask for advanced highly active drug solutions. We (and our technology) will support them.

supply risk mitigation

We understand the cost and time pressures faced by pharmaceutical companies, therefore we offer flexible, affordable, and rapid outsourcing services designed to meet specific needs of our customers.

access to free manufacturing capacity

We offer two fully operational lines. We also keep investing into manufacturing capacity and state-of-the-art technologies. Line 3 that will offer highly advanced solutions is in construction.

no additional major investments

We offer various vial formats, variable equipment sizes and qualified processes. We also take pride in our transparent service offerings that lower any additional investments to a mere minimum.

upcoming events

CPhI Worldwide 2023

conference, networking

24 Oct – 26 Oct 2023

Barcelona, Spain

Each year CPhI unites more than 100,000 pharmaceutical professionals through exhibitions, conferences and online communities to network, identify business opportunities and expand the global market.

news & stories

27. 9. 2023 | Articles News

Launch of RABS

According to Annex 1, the introduction of the RABS represents a significant step forward in the field of pharmaceutical production. Read more about the implementation in oncomed.
read text
29. 8. 2023 | Articles News

Successful FAT of Line 3

A FAT is an important step in the manufacturing process, and we are happy to share that we successfully completed it for Line 3.
read text
19. 7. 2023 | Articles News

New formulation vessel for Line 1

We introduced a new stationary formulation vessel with a volume of 1,500 litres labelled as K1 for the formulation on Line 1.
read text